Salim Syed
Stock Analyst at Mizuho
(1.96)
# 1,619
Out of 4,412 analysts
56
Total ratings
28.85%
Success rate
-2.71%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $17.18 | +97.90% | 1 | Apr 9, 2024 | |
| NKTX Nkarta | Maintains: Buy | $31 → $25 | $6.87 | +263.90% | 6 | Mar 22, 2024 | |
| WVE Wave Life Sciences | Maintains: Buy | $10 → $19 | $4.66 | +307.73% | 3 | Mar 12, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $69 → $113 | $60.72 | +86.10% | 2 | Mar 12, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $103 → $99 | $65.34 | +51.52% | 4 | Mar 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $53.91 | +83.64% | 3 | Mar 6, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $53 | $24.88 | +113.02% | 7 | Mar 5, 2024 | |
| GILD Gilead Sciences | Maintains: Buy | $101 → $90 | $65.42 | +37.57% | 4 | Feb 22, 2024 | |
| BIIB Biogen | Maintains: Buy | $355 → $277 | $208.90 | +32.60% | 11 | Feb 22, 2024 | |
| ATRA Atara Biotherapeutics | Downgrades: Neutral | $31 → $1 | $0.69 | +44.93% | 3 | Nov 9, 2023 | |
| AMGN Amgen | Maintains: Neutral | $214 → $223 | $269.98 | -17.40% | 4 | Aug 14, 2023 | |
| UBX Unity Biotechnology | Maintains: Buy | $12 → $6 | $1.50 | +300.00% | 4 | Mar 28, 2023 | |
| CHRS Coherus BioSciences | Maintains: Buy | $28 → $21 | $2.04 | +929.41% | 3 | Nov 16, 2022 | |
| ASMB Assembly Biosciences | Maintains: Buy | $168 → $36 | $12.65 | +184.58% | 1 | Nov 16, 2022 |
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $17.18
Upside: +97.90%
Nkarta
Mar 22, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.87
Upside: +263.90%
Wave Life Sciences
Mar 12, 2024
Maintains: Buy
Price Target: $10 → $19
Current: $4.66
Upside: +307.73%
Vaxcyte
Mar 12, 2024
Maintains: Buy
Price Target: $69 → $113
Current: $60.72
Upside: +86.10%
Cytokinetics
Mar 6, 2024
Maintains: Buy
Price Target: $103 → $99
Current: $65.34
Upside: +51.52%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $53.91
Upside: +83.64%
BridgeBio Pharma
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $24.88
Upside: +113.02%
Gilead Sciences
Feb 22, 2024
Maintains: Buy
Price Target: $101 → $90
Current: $65.42
Upside: +37.57%
Biogen
Feb 22, 2024
Maintains: Buy
Price Target: $355 → $277
Current: $208.90
Upside: +32.60%
Atara Biotherapeutics
Nov 9, 2023
Downgrades: Neutral
Price Target: $31 → $1
Current: $0.69
Upside: +44.93%
Amgen
Aug 14, 2023
Maintains: Neutral
Price Target: $214 → $223
Current: $269.98
Upside: -17.40%
Unity Biotechnology
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.50
Upside: +300.00%
Coherus BioSciences
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $2.04
Upside: +929.41%
Assembly Biosciences
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $12.65
Upside: +184.58%